These combinations will likely improve the survival outlook for patients with multiple myeloma.doi:10.1634/theoncologist.2017-0229VishalBhatnagarNicole JGormleyLolaLuoYuan LiShenRajeshwariSridharaThe oncologistBhatnagar V, Gormley NJ, Luo L et al. FDA approval summary: daratumumab for treatment of multiple...
1. Johnson & Johnson submits supplemental biologics license application to U.S. FDA seeking approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma. News release. Johnson & Johnson. Janu...
1. Johnson & Johnson submits supplemental biologics license application to U.S. FDA seeking approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma. News release. Johnson & Johnson. Janu...
Advances in the treatment of multiple myeloma (MM), particularly the development of immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) and the use of autologous hematopoietic stem cell transplantation, have led to significant improvement in overall survival in patients with MM [1,2]. Nev...
It is an established treatment for Multiple Myeloma (MM) [1]. Currently, there are over 300 clinical trials testing DARA and other anti-CD38 antibodies (e.g., HuMax-CD38 and JNJ-54767414) [2]. CD38 is expressed on a variety of hematopoietic cells and immune cells like plasma cells(PC)...
(1)Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13): 1207-1219. (2)Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with ...
Daratumumab: the first anti-CD38 monoclonal antibody for the treatment of multiple myelomaCyrille TouzeauBenjamin HébraudXavier Leleu
小工具 Daratumumab;达雷木单抗 产品简介: Daratumumab is a recombinant IgG1k monoclonal antibody that binds to CD38 and leads to cell apoptosis. Daratumumab was granted orphan drug designation for the treatment of multiple myeloma, diffuse large B cell lymphoma, follicular lymphoma, and mantle cell lymp...
In the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/bortezomib/de
The sBLA for a daratumumab (Darzalex)-based regimen for the treatment of newly diagnosed multiple myeloma has been submitted to the FDA, according to a press release from Johnson & Johnson.1 The application is based on findings from the phase 3 PERSEUS study. The regimen is comprised of darat...